Publication
Title
Current concepts for the management of head and neck cancer: chemotherapy
Author
Abstract
Chemotherapy can be administered in patients with locoregionally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) either concurrently with irradiation or as induction chemotherapy prior to local treatment or as palliative therapy in patients with recurrent and/or metastatic disease. Cisplatin-based chemoradiation is still the standard for LASCCHN. TPF has emerged as the new standard regimen when induction chemotherapy is indicated. Areas of active investigation in LASCCHN are the sequential administration of induction chemotherapy followed by chemoradiation and the integration of targeted therapies. None of the combination chemotherapy regimens demonstrated an overall survival benefit when compared to single agent methotrexate, cisplatin or 5-fluorouracil in recurrent/metastatic disease. Combination chemotherapy in this setting is preferably used in younger patients with a good performance status and with symptomatic disease who require prompt symptom relief. However, a survival benefit was observed when cetuximab was combined with platinum-5-fluorouracil.
Language
English
Source (journal)
Oral oncology. - Oxford, 1997, currens
Publication
Oxford : 2009
ISSN
1368-8375
Volume/pages
45:4/5(2009), p. 409-415
ISI
000265682700014
Full text (Publishers DOI)
Full text (publishers version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 22.06.2009
Last edited 18.05.2017
To cite this reference